25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

IRLAB Therapeutics AB (publ)
Buy, Hold or Sell?

Let's analyze Irlab together

I guess you are interested in IRLAB Therapeutics AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of IRLAB Therapeutics AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about IRLAB Therapeutics AB (publ)

I send you an email if I find something interesting about IRLAB Therapeutics AB (publ).

1. Quick Overview

1.1. Quick analysis of Irlab (30 sec.)










1.2. What can you expect buying and holding a share of Irlab? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.73
Expected worth in 1 year
kr-1.39
How sure are you?
22.9%

+ What do you gain per year?

Total Gains per Share
kr-2.12
Return On Investment
-16.2%

For what price can you sell your share?

Current Price per Share
kr13.10
Expected price per share
kr9.88 - kr14.35
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Irlab (5 min.)




Live pricePrice per Share (EOD)
kr13.10
Intrinsic Value Per Share
kr-205.35 - kr-246.35
Total Value Per Share
kr-204.62 - kr-245.62

2.2. Growth of Irlab (5 min.)




Is Irlab growing?

Current yearPrevious yearGrowGrow %
How rich?$3.4m$19.6m-$12.7m-185.3%

How much money is Irlab making?

Current yearPrevious yearGrowGrow %
Making money-$2.5m-$4m$1.4m56.3%
Net Profit Margin642.0%-231.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Irlab (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Irlab?

Welcome investor! Irlab's management wants to use your money to grow the business. In return you get a share of Irlab.

First you should know what it really means to hold a share of Irlab. And how you can make/lose money.

Speculation

The Price per Share of Irlab is kr13.10. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Irlab.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Irlab, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.73. Based on the TTM, the Book Value Change Per Share is kr-0.53 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Irlab.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.06-0.4%-0.05-0.4%-0.08-0.6%-0.04-0.3%-0.03-0.3%
Usd Book Value Change Per Share-0.06-0.4%-0.05-0.4%-0.08-0.6%-0.01-0.1%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.06-0.4%-0.05-0.4%-0.08-0.6%-0.01-0.1%0.000.0%
Usd Price Per Share1.16-1.12-1.50-2.60-2.77-
Price to Earnings Ratio-5.20--9.38--5.59--13.68--22.82-
Price-to-Total Gains Ratio-20.81--37.75--22.38--39.68--51.40-
Price to Book Ratio17.32-10.27-3.58-6.59-9.10-
Price-to-Total Gains Ratio-20.81--37.75--22.38--39.68--51.40-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.20127
Number of shares832
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.05-0.01
Usd Total Gains Per Share-0.05-0.01
Gains per Quarter (832 shares)-40.43-7.72
Gains per Year (832 shares)-161.72-30.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-162-1720-31-41
20-323-3340-62-72
30-485-4960-93-103
40-647-6580-123-134
50-809-8200-154-165
60-970-9820-185-196
70-1132-11440-216-227
80-1294-13060-247-258
90-1456-14680-278-289
100-1617-16300-309-320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.034.00.02.9%1.034.00.02.9%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%8.024.03.022.9%8.024.03.022.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.035.00.0%0.00.035.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%8.024.03.022.9%8.024.03.022.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of IRLAB Therapeutics AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.610-0.530-13%-0.848+39%-0.101-83%0.021-3014%
Book Value Per Share--0.7331.447-49%4.130-82%4.815-85%3.840-81%
Current Ratio--0.8701.958-56%5.186-83%6.943-87%7.236-88%
Debt To Asset Ratio--0.7630.556+37%0.166+358%0.207+268%0.143+432%
Debt To Equity Ratio--3.2151.651+95%0.202+1489%0.442+627%0.280+1048%
Dividend Per Share----0%-0%-0%-0%
Eps---0.610-0.543-11%-0.849+39%-0.420-31%-0.367-40%
Free Cash Flow Per Share---0.098-0.372+280%-0.817+734%-0.330+237%-0.308+215%
Free Cash Flow To Equity Per Share---0.152-0.137-10%-0.834+448%0.022-796%0.050-406%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---246.353--------
Intrinsic Value_10Y_min---205.355--------
Intrinsic Value_1Y_max---5.687--------
Intrinsic Value_1Y_min---5.575--------
Intrinsic Value_3Y_max---31.567--------
Intrinsic Value_3Y_min---29.844--------
Intrinsic Value_5Y_max---74.904--------
Intrinsic Value_5Y_min---68.277--------
Market Cap678430660.000+3%658728756.200636036328.575+4%848086717.510-22%1468717155.245-55%1890251396.971-65%
Net Profit Margin---3.5056.420-155%-2.316-34%66.051-105%-101.978+2809%
Operating Margin---3.1806.498-149%-2.312-27%65.944-105%-103.877+3167%
Operating Ratio--5.065-12.587+349%5.591-9%-118.935+2448%176.487-97%
Pb Ratio17.867+3%17.32210.272+69%3.577+384%6.588+163%9.103+90%
Pe Ratio-5.366-3%-5.202-9.378+80%-5.594+8%-13.684+163%-22.816+339%
Price Per Share13.100+3%12.70012.263+4%16.355-22%28.349-55%30.226-58%
Price To Free Cash Flow Ratio-33.459-3%-32.437395.072-108%-5.301-84%67.781-148%24.221-234%
Price To Total Gains Ratio-21.462-3%-20.807-37.748+81%-22.375+8%-39.685+91%-51.403+147%
Quick Ratio--0.8701.937-55%5.157-83%6.925-87%7.144-88%
Return On Assets---0.198-0.178-10%-0.180-9%-0.100-49%-0.090-54%
Return On Equity---0.832-0.436-48%-0.218-74%-0.162-81%-0.137-84%
Total Gains Per Share---0.610-0.530-13%-0.848+39%-0.101-83%0.021-3014%
Usd Book Value--3487259.3006882703.975-49%19634185.025-82%22876669.515-85%18695675.480-81%
Usd Book Value Change Per Share---0.056-0.049-13%-0.078+39%-0.009-83%0.002-3014%
Usd Book Value Per Share--0.0670.133-49%0.379-82%0.442-85%0.352-81%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.056-0.050-11%-0.078+39%-0.038-31%-0.034-40%
Usd Free Cash Flow---465560.900-1767265.325+280%-3883128.200+734%-1568505.575+237%-1501854.740+223%
Usd Free Cash Flow Per Share---0.009-0.034+280%-0.075+734%-0.030+237%-0.028+215%
Usd Free Cash Flow To Equity Per Share---0.014-0.013-10%-0.076+448%0.002-796%0.005-406%
Usd Market Cap62212091.522+3%60405426.94458324531.330+4%77769551.996-22%134681363.136-55%173336053.102-65%
Usd Price Per Share1.201+3%1.1651.124+4%1.500-22%2.600-55%2.772-58%
Usd Profit---2903038.600-2584083.075-11%-4038238.750+39%-1997106.790-31%-1777242.940-39%
Usd Revenue--828142.7001160371.800-29%436744.175+90%1498116.655-45%857298.060-3%
Usd Total Gains Per Share---0.056-0.049-13%-0.078+39%-0.009-83%0.002-3014%
 EOD+5 -3MRQTTM+8 -25YOY+17 -165Y+6 -2710Y+9 -24

3.3 Fundamental Score

Let's check the fundamental score of IRLAB Therapeutics AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.366
Price to Book Ratio (EOD)Between0-117.867
Net Profit Margin (MRQ)Greater than0-3.505
Operating Margin (MRQ)Greater than0-3.180
Quick Ratio (MRQ)Greater than10.870
Current Ratio (MRQ)Greater than10.870
Debt to Asset Ratio (MRQ)Less than10.763
Debt to Equity Ratio (MRQ)Less than13.215
Return on Equity (MRQ)Greater than0.15-0.832
Return on Assets (MRQ)Greater than0.05-0.198
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of IRLAB Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose13.100
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About IRLAB Therapeutics AB (publ)

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson's; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.

Fundamental data was last updated by Penke on 2024-11-14 17:53:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Irlab earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Irlab to the Biotechnology industry mean.
  • A Net Profit Margin of -350.5% means that kr-3.51 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of IRLAB Therapeutics AB (publ):

  • The MRQ is -350.5%. The company is making a huge loss. -2
  • The TTM is 642.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-350.5%TTM642.0%-992.5%
TTM642.0%YOY-231.6%+873.6%
TTM642.0%5Y6,605.1%-5,963.1%
5Y6,605.1%10Y-10,197.8%+16,802.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-350.5%-113.9%-236.6%
TTM642.0%-214.4%+856.4%
YOY-231.6%-210.0%-21.6%
5Y6,605.1%-339.1%+6,944.2%
10Y-10,197.8%-464.5%-9,733.3%
4.3.1.2. Return on Assets

Shows how efficient Irlab is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Irlab to the Biotechnology industry mean.
  • -19.8% Return on Assets means that Irlab generated kr-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of IRLAB Therapeutics AB (publ):

  • The MRQ is -19.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.8%TTM-17.8%-1.9%
TTM-17.8%YOY-18.0%+0.1%
TTM-17.8%5Y-10.0%-7.8%
5Y-10.0%10Y-9.0%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.8%-11.1%-8.7%
TTM-17.8%-11.7%-6.1%
YOY-18.0%-11.3%-6.7%
5Y-10.0%-12.7%+2.7%
10Y-9.0%-14.3%+5.3%
4.3.1.3. Return on Equity

Shows how efficient Irlab is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Irlab to the Biotechnology industry mean.
  • -83.2% Return on Equity means Irlab generated kr-0.83 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of IRLAB Therapeutics AB (publ):

  • The MRQ is -83.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -43.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-83.2%TTM-43.6%-39.6%
TTM-43.6%YOY-21.8%-21.8%
TTM-43.6%5Y-16.2%-27.4%
5Y-16.2%10Y-13.7%-2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-83.2%-14.2%-69.0%
TTM-43.6%-15.8%-27.8%
YOY-21.8%-14.2%-7.6%
5Y-16.2%-18.5%+2.3%
10Y-13.7%-19.5%+5.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of IRLAB Therapeutics AB (publ).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Irlab is operating .

  • Measures how much profit Irlab makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Irlab to the Biotechnology industry mean.
  • An Operating Margin of -318.0% means the company generated kr-3.18  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of IRLAB Therapeutics AB (publ):

  • The MRQ is -318.0%. The company is operating very inefficient. -2
  • The TTM is 649.8%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ-318.0%TTM649.8%-967.8%
TTM649.8%YOY-231.2%+881.0%
TTM649.8%5Y6,594.4%-5,944.6%
5Y6,594.4%10Y-10,387.7%+16,982.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-318.0%-224.9%-93.1%
TTM649.8%-306.4%+956.2%
YOY-231.2%-223.5%-7.7%
5Y6,594.4%-386.5%+6,980.9%
10Y-10,387.7%-497.6%-9,890.1%
4.3.2.2. Operating Ratio

Measures how efficient Irlab is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 5.06 means that the operating costs are kr5.06 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of IRLAB Therapeutics AB (publ):

  • The MRQ is 5.065. The company is inefficient in keeping operating costs low. -1
  • The TTM is -12.587.
Trends
Current periodCompared to+/- 
MRQ5.065TTM-12.587+17.652
TTM-12.587YOY5.591-18.178
TTM-12.5875Y-118.935+106.348
5Y-118.93510Y176.487-295.423
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0652.508+2.557
TTM-12.5873.295-15.882
YOY5.5913.298+2.293
5Y-118.9354.788-123.723
10Y176.4876.517+169.970
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of IRLAB Therapeutics AB (publ).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Irlab is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.87 means the company has kr0.87 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of IRLAB Therapeutics AB (publ):

  • The MRQ is 0.870. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.958. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.870TTM1.958-1.089
TTM1.958YOY5.186-3.227
TTM1.9585Y6.943-4.985
5Y6.94310Y7.236-0.293
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8703.645-2.775
TTM1.9583.877-1.919
YOY5.1864.666+0.520
5Y6.9435.938+1.005
10Y7.2366.265+0.971
4.4.3.2. Quick Ratio

Measures if Irlab is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Irlab to the Biotechnology industry mean.
  • A Quick Ratio of 0.87 means the company can pay off kr0.87 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of IRLAB Therapeutics AB (publ):

  • The MRQ is 0.870. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.937. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.870TTM1.937-1.068
TTM1.937YOY5.157-3.220
TTM1.9375Y6.925-4.987
5Y6.92510Y7.144-0.219
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8703.093-2.223
TTM1.9373.432-1.495
YOY5.1574.478+0.679
5Y6.9255.927+0.998
10Y7.1446.424+0.720
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of IRLAB Therapeutics AB (publ).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Irlab assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Irlab to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.76 means that Irlab assets are financed with 76.3% credit (debt) and the remaining percentage (100% - 76.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of IRLAB Therapeutics AB (publ):

  • The MRQ is 0.763. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.556. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.763TTM0.556+0.207
TTM0.556YOY0.166+0.389
TTM0.5565Y0.207+0.348
5Y0.20710Y0.143+0.064
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7630.354+0.409
TTM0.5560.345+0.211
YOY0.1660.311-0.145
5Y0.2070.366-0.159
10Y0.1430.383-0.240
4.5.4.2. Debt to Equity Ratio

Measures if Irlab is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Irlab to the Biotechnology industry mean.
  • A Debt to Equity ratio of 321.5% means that company has kr3.21 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of IRLAB Therapeutics AB (publ):

  • The MRQ is 3.215. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.651. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ3.215TTM1.651+1.564
TTM1.651YOY0.202+1.449
TTM1.6515Y0.442+1.209
5Y0.44210Y0.280+0.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2150.396+2.819
TTM1.6510.436+1.215
YOY0.2020.380-0.178
5Y0.4420.451-0.009
10Y0.2800.493-0.213
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Irlab generates.

  • Above 15 is considered overpriced but always compare Irlab to the Biotechnology industry mean.
  • A PE ratio of -5.20 means the investor is paying kr-5.20 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of IRLAB Therapeutics AB (publ):

  • The EOD is -5.366. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.202. Based on the earnings, the company is expensive. -2
  • The TTM is -9.378. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.366MRQ-5.202-0.164
MRQ-5.202TTM-9.378+4.176
TTM-9.378YOY-5.594-3.784
TTM-9.3785Y-13.684+4.306
5Y-13.68410Y-22.816+9.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.366-2.220-3.146
MRQ-5.202-2.398-2.804
TTM-9.378-3.148-6.230
YOY-5.594-3.237-2.357
5Y-13.684-6.033-7.651
10Y-22.816-6.685-16.131
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of IRLAB Therapeutics AB (publ):

  • The EOD is -33.459. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -32.437. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 395.072. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-33.459MRQ-32.437-1.022
MRQ-32.437TTM395.072-427.509
TTM395.072YOY-5.301+400.373
TTM395.0725Y67.781+327.291
5Y67.78110Y24.221+43.560
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-33.459-2.988-30.471
MRQ-32.437-3.276-29.161
TTM395.072-3.734+398.806
YOY-5.301-4.523-0.778
5Y67.781-8.321+76.102
10Y24.221-9.273+33.494
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Irlab is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 17.32 means the investor is paying kr17.32 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of IRLAB Therapeutics AB (publ):

  • The EOD is 17.867. Based on the equity, the company is expensive. -2
  • The MRQ is 17.322. Based on the equity, the company is expensive. -2
  • The TTM is 10.272. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD17.867MRQ17.322+0.546
MRQ17.322TTM10.272+7.050
TTM10.272YOY3.577+6.695
TTM10.2725Y6.588+3.684
5Y6.58810Y9.103-2.515
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.8671.894+15.973
MRQ17.3222.027+15.295
TTM10.2722.356+7.916
YOY3.5772.418+1.159
5Y6.5883.686+2.902
10Y9.1034.357+4.746
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Other Current Liabilities  37,642-14,37423,2689,04632,31458,53490,848-90,849-1
Net Working Capital  96,241-9,38586,856-36,95249,904-28,84821,056-36,422-15,366



6.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in SEK. All numbers in thousands.

Summary
Total Assets160,292
Total Liabilities122,263
Total Stockholder Equity38,030
 As reported
Total Liabilities 122,263
Total Stockholder Equity+ 38,030
Total Assets = 160,292

Assets

Total Assets160,292
Total Current Assets102,513
Long-term Assets57,779
Total Current Assets
Cash And Cash Equivalents 90,383
Net Receivables 12,130
Total Current Assets  (as reported)102,513
Total Current Assets  (calculated)102,513
+/-0
Long-term Assets
Property Plant Equipment 10,917
Intangible Assets 46,862
Long-term Assets  (as reported)57,779
Long-term Assets  (calculated)57,779
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities117,879
Long-term Liabilities4,384
Total Stockholder Equity38,030
Total Current Liabilities
Short-term Debt 55,904
Accounts payable 61,976
Other Current Liabilities -1
Total Current Liabilities  (as reported)117,879
Total Current Liabilities  (calculated)117,879
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)4,384
Long-term Liabilities  (calculated)0
+/- 4,384
Total Stockholder Equity
Common Stock1,037
Retained Earnings -653,213
Other Stockholders Equity 690,206
Total Stockholder Equity (as reported)38,030
Total Stockholder Equity (calculated)38,030
+/-0
Other
Cash and Short Term Investments 90,383
Common Stock Shares Outstanding 51,868
Liabilities and Stockholders Equity 160,293
Net Debt -34,479
Net Working Capital -15,366
Short Long Term Debt Total 55,904



6.3. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
> Total Assets 
0
0
0
113,112
208,025
193,742
184,680
162,971
150,165
263,856
241,794
224,936
212,115
189,063
164,316
208,067
315,493
296,335
264,847
370,068
352,295
327,119
498,391
472,449
434,850
396,003
368,772
323,555
277,453
229,987
186,915
177,121
136,667
214,612
160,292
160,292214,612136,667177,121186,915229,987277,453323,555368,772396,003434,850472,449498,391327,119352,295370,068264,847296,335315,493208,067164,316189,063212,115224,936241,794263,856150,165162,971184,680193,742208,025113,112000
   > Total Current Assets 
14,424
0
0
28,194
123,195
109,001
99,977
78,224
64,923
178,647
156,564
140,470
121,650
99,120
74,867
119,878
227,761
208,894
177,949
283,741
260,015
235,381
446,534
421,440
384,463
345,906
312,759
268,684
223,369
176,988
134,996
123,587
84,285
163,382
102,513
102,513163,38284,285123,587134,996176,988223,369268,684312,759345,906384,463421,440446,534235,381260,015283,741177,949208,894227,761119,87874,86799,120121,650140,470156,564178,64764,92378,22499,977109,001123,19528,1940014,424
       Cash And Cash Equivalents 
-14,424
0
0
25,736
120,437
106,810
96,095
74,709
60,726
170,178
151,917
134,442
116,878
91,594
68,011
110,527
221,509
201,784
169,693
277,009
253,905
229,383
431,168
401,897
368,047
322,615
291,749
252,776
210,103
156,413
118,814
111,309
73,140
98,272
90,383
90,38398,27273,140111,309118,814156,413210,103252,776291,749322,615368,047401,897431,168229,383253,905277,009169,693201,784221,509110,52768,01191,594116,878134,442151,917170,17860,72674,70996,095106,810120,43725,73600-14,424
       Short-term Investments 
28,848
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000028,848
       Net Receivables 
0
0
0
0
2,758
2,191
3,882
19
0
0
0
0
0
7,525
6,856
7,687
6,252
7,110
8,256
4,711
6,111
5,997
15,365
19,542
16,416
23,291
21,010
12,217
13,267
20,575
16,182
9,167
11,146
65,110
12,130
12,13065,11011,1469,16716,18220,57513,26712,21721,01023,29116,41619,54215,3655,9976,1114,7118,2567,1106,2527,6876,8567,52500000193,8822,1912,7580000
       Other Current Assets 
0
0
0
2,458
2,758
2,191
3,882
3,515
4,197
8,469
1
-1
4,772
1
6,856
9,351
6,252
7,110
8,256
1
-1
1
1
1
16,416
23,291
21,010
-1
-1
0
0
12,592
11,145
65,110
0
065,11011,14512,59200-1-121,01023,29116,416111-118,2567,1106,2529,3516,85614,772-118,4694,1973,5153,8822,1912,7582,458000
   > Long-term Assets 
-14,424
0
0
84,918
84,830
84,741
84,703
84,747
85,242
85,208
85,231
84,466
90,465
89,943
89,450
88,189
87,732
87,441
86,898
86,328
92,280
91,738
51,859
51,009
50,387
50,097
56,013
54,871
54,084
52,999
51,919
53,534
52,382
51,230
57,779
57,77951,23052,38253,53451,91952,99954,08454,87156,01350,09750,38751,00951,85991,73892,28086,32886,89887,44187,73288,18989,45089,94390,46584,46685,23185,20885,24284,74784,70384,74184,83084,91800-14,424
       Property Plant Equipment 
0
0
0
649
561
472
435
478
1,043
1,069
1,157
1,197
7,260
6,804
6,375
5,919
5,527
5,301
4,822
4,317
10,334
9,857
9,133
8,348
7,791
7,566
8,290
8,009
7,222
6,137
5,057
6,672
5,520
4,369
10,917
10,9174,3695,5206,6725,0576,1377,2228,0098,2907,5667,7918,3489,1339,85710,3344,3174,8225,3015,5275,9196,3756,8047,2601,1971,1571,0691,043478435472561649000
       Intangible Assets 
0
0
0
84,269
84,269
84,269
84,269
84,269
84,199
84,139
84,074
83,269
83,204
83,140
83,075
82,270
82,205
82,140
82,076
82,011
81,946
81,881
42,726
42,661
42,596
42,531
47,723
46,862
46,862
46,862
46,862
46,862
46,862
46,862
46,862
46,86246,86246,86246,86246,86246,86246,86246,86247,72342,53142,59642,66142,72681,88181,94682,01182,07682,14082,20582,27083,07583,14083,20483,26984,07484,13984,19984,26984,26984,26984,26984,269000
       Long-term Assets Other 
-14,424
0
0
0
0
0
-1
0
0
0
0
0
1
-1
0
0
0
0
0
0
0
81,881
42,726
0
42,596
-50,097
0
-54,871
-54,084
-52,999
-51,919
-1
46,862
-1
0
0-146,862-1-51,919-52,999-54,084-54,8710-50,09742,596042,72681,8810000000-1100000-100000-14,424
> Total Liabilities 
0
0
0
9,223
8,694
5,055
16,680
7,971
11,016
16,957
10,702
12,460
17,362
24,776
21,584
26,240
17,155
24,336
20,742
22,188
24,456
25,909
75,794
72,968
64,539
52,807
44,776
32,724
46,178
43,617
38,938
61,357
59,921
144,924
122,263
122,263144,92459,92161,35738,93843,61746,17832,72444,77652,80764,53972,96875,79425,90924,45622,18820,74224,33617,15526,24021,58424,77617,36212,46010,70216,95711,0167,97116,6805,0558,6949,223000
   > Total Current Liabilities 
0
0
0
8,823
8,294
5,055
16,680
7,971
11,016
16,957
10,702
12,460
13,236
24,776
21,584
23,340
14,674
22,397
19,973
20,918
18,600
20,806
71,456
69,402
61,734
50,814
43,584
32,343
45,863
43,368
38,755
36,731
34,381
142,326
117,879
117,879142,32634,38136,73138,75543,36845,86332,34343,58450,81461,73469,40271,45620,80618,60020,91819,97322,39714,67423,34021,58424,77613,23612,46010,70216,95711,0167,97116,6805,0558,2948,823000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,584
0
0
1,643
1,663
1,667
1,654
1,657
2,925
2,961
2,998
3,034
3,051
3,109
3,148
3,595
2,778
1,951
1,113
2,940
2,067
52,633
55,904
55,90452,6332,0672,9401,1131,9512,7783,5953,1483,1093,0513,0342,9982,9612,9251,6571,6541,6671,6631,643001,584000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
51,478
0
051,478000000000000000000000000000000000
       Accounts payable 
0
0
0
4,729
0
0
0
4,099
0
0
0
5,997
0
0
0
8,438
0
0
0
3,683
15,674
17,845
68,458
12,302
58,684
47,705
40,437
10,031
43,085
41,417
37,642
10,523
32,314
89,693
61,976
61,97689,69332,31410,52337,64241,41743,08510,03140,43747,70558,68412,30268,45817,84515,6743,6830008,4380005,9970004,0990004,729000
       Other Current Liabilities 
0
0
0
4,094
8,294
5,055
16,680
3,872
11,016
16,957
10,702
6,463
11,652
24,776
21,584
5,445
13,011
20,730
18,319
3,773
15,675
17,845
68,458
5,646
58,683
47,705
40,436
18,717
43,085
41,417
37,642
23,268
32,314
90,848
-1
-190,84832,31423,26837,64241,41743,08518,71740,43647,70558,6835,64668,45817,84515,6753,77318,31920,73013,0115,44521,58424,77611,6526,46310,70216,95711,0163,87216,6805,0558,2944,094000
   > Long-term Liabilities 
0
0
0
400
400
0
0
4,099
0
0
0
5,997
4,126
0
0
2,900
2,481
1,939
769
1,270
5,856
5,103
4,338
3,566
2,805
1,993
1,192
381
315
249
183
24,626
25,540
2,598
4,384
4,3842,59825,54024,6261832493153811,1921,9932,8053,5664,3385,1035,8561,2707691,9392,4812,900004,1265,9970004,09900400400000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
769
1,270
5,856
5,102
4,339
3,566
2,805
1,993
1,191
381
315
249
182
0
0
0
0
00001822493153811,1911,9932,8053,5664,3395,1025,8561,270769000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
-1
0
0
0
1
0
0
0
0
0
0
0
0
000000001000-11000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
777
0
0
0
518
0
0
0
259
0
0
0
0
0
0
0
0
0
0
0
00000000000259000518000777000000000000000
> Total Stockholder Equity
92,027
0
0
103,889
199,331
188,687
168,000
155,000
139,149
246,899
231,092
212,476
194,753
164,287
142,732
181,826
298,338
271,999
244,105
347,880
327,839
301,210
422,597
399,481
370,311
343,196
323,996
290,831
231,275
186,370
147,977
115,764
76,745
69,688
38,030
38,03069,68876,745115,764147,977186,370231,275290,831323,996343,196370,311399,481422,597301,210327,839347,880244,105271,999298,338181,826142,732164,287194,753212,476231,092246,899139,149155,000168,000188,687199,331103,8890092,027
   Common Stock
0
0
0
507
700
700
700
700
700
810
810
810
810
810
810
862
970
970
970
1,035
1,035
1,035
1,035
1,035
1,035
1,035
1,037
1,037
1,037
1,037
1,037
1,037
1,037
1,037
1,037
1,0371,0371,0371,0371,0371,0371,0371,0371,0371,0351,0351,0351,0351,0351,0351,035970970970862810810810810810810700700700700700507000
   Retained Earnings Total Equity00000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
92,027
0
0
0
0
-1
1
0
0
0
0
0
0
0
0
1
0
0
0
65
686,665
0
1
0
0
0
0
1
0
0
0
0
0
0
0
00000001000010686,665650001000000001-1000092,027
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
428,097
563,618
563,433
562,454
685,630
685,630
685,630
607,659
685,450
685,450
685,450
690,204
690,205
690,205
690,205
690,204
0
0
0
0
0000690,204690,205690,205690,205690,204685,450685,450685,450607,659685,630685,630685,630562,454563,433563,618428,097000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
124,071
231,214
231,214
231,214
231,214
231,214
362,679
362,679
362,679
362,679
362,679
362,679
428,096
563,618
563,433
562,454
685,566
-1,035
685,630
607,658
685,450
685,450
685,450
690,204
690,204
690,205
690,205
690,204
690,205
690,205
690,205
690,206
690,206690,205690,205690,205690,204690,205690,205690,204690,204685,450685,450685,450607,658685,630-1,035685,566562,454563,433563,618428,096362,679362,679362,679362,679362,679362,679231,214231,214231,214231,214231,214124,071000



6.4. Balance Sheets

Currency in SEK. All numbers in thousands.




6.5. Cash Flows

Currency in SEK. All numbers in thousands.




6.6. Income Statements

Currency in SEK. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue5,678
Cost of Revenue-128,412
Gross Profit-122,734-122,734
 
Operating Income (+$)
Gross Profit-122,734
Operating Expense-58,031
Operating Income-180,765-180,765
 
Operating Expense (+$)
Research Development151,312
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense58,031151,312
 
Net Interest Income (+$)
Interest Income2,379
Interest Expense-198
Other Finance Cost-1
Net Interest Income2,180
 
Pretax Income (+$)
Operating Income-180,765
Net Interest Income2,180
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-177,839-183,691
EBIT - interestExpense = -177,838
-173,691
-177,641
Interest Expense198
Earnings Before Interest and Taxes (EBIT)-177,640-177,641
Earnings Before Interest and Taxes (EBITDA)-173,324
 
After tax Income (+$)
Income Before Tax-177,839
Tax Provision-0
Net Income From Continuing Ops-176,019-177,839
Net Income-177,839
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses186,443
Total Other Income/Expenses Net2,926-2,180
 

Technical Analysis of Irlab
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Irlab. The general trend of Irlab is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Irlab's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of IRLAB Therapeutics AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 14.30 < 14.35 < 14.35.

The bearish price targets are: 11.40 > 11.30 > 9.88.

Tweet this
IRLAB Therapeutics AB (publ) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of IRLAB Therapeutics AB (publ). The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

IRLAB Therapeutics AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartIRLAB Therapeutics AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of IRLAB Therapeutics AB (publ). The current adx is .

IRLAB Therapeutics AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Relative Strength Index (RSI) ChartIRLAB Therapeutics AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Stochastic Oscillator ChartIRLAB Therapeutics AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Commodity Channel Index (CCI) ChartIRLAB Therapeutics AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Chande Momentum Oscillator (CMO) ChartIRLAB Therapeutics AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Williams %R ChartIRLAB Therapeutics AB (publ) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Average True Range (ATR) ChartIRLAB Therapeutics AB (publ) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily On-Balance Volume (OBV) ChartIRLAB Therapeutics AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of IRLAB Therapeutics AB (publ).

IRLAB Therapeutics AB (publ) Daily Money Flow Index (MFI) ChartIRLAB Therapeutics AB (publ) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for IRLAB Therapeutics AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-10-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

IRLAB Therapeutics AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of IRLAB Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose13.100
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Irlab with someone you think should read this too:
  • Are you bullish or bearish on Irlab? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Irlab? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about IRLAB Therapeutics AB (publ)

I send you an email if I find something interesting about IRLAB Therapeutics AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about IRLAB Therapeutics AB (publ).

Receive notifications about IRLAB Therapeutics AB (publ) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.